166 results
8-K
EX-10.6
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent may be brought in its name as the Rights Agent and any recovery … to the Company to audit such records for the sole purpose of confirming payments for a period covering not more than the date commencing with the first CVR
8-K
EX-14.1
xzlxlgs33rh1fjnh
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-99.4
cijwqh9p4b 25akwrn
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
f6ghsu6p nph32
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
svi b5i3ljggwwqzujh
4 Dec 23
Business combination disclosure
5:14pm
8-K
EX-10.1
ifkd9vh2h
4 Dec 23
Other Events
5:10pm
S-4/A
EX-10.33
tzbzeq4 yj
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
g7dm3yoi6mrj7vpwb hv
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.31
1stc5op20yrttwdq2g8l
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.35
bzg3nk ne6rfi8yu9r
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm